Enhancement of Functionality and Therapeutic Efficacy of Cell-Based Therapy Using Mesenchymal Stem Cells for Cardiovascular Disease

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2019 Mar 1

PMID 30813471

Citations 25

Authors

Chul Won Yun

Sang Hun Lee

Affiliations

Soon will be listed here.

Abstract

Cardiovascular disease usually triggers coronary heart disease, stroke, and ischemic diseases, thus promoting the development of functional failure. Mesenchymal stem cells (MSCs) are cells that can be isolated from various human tissues, with multipotent and immunomodulatory characteristics to help damaged tissue repair and avoidance of immune responses. Much research has proved the feasibility, safety, and efficiency of MSC-based therapy for cardiovascular disease. Despite the fact that the precise mechanism of MSCs remains unclear, their therapeutic capability to treat ischemic diseases has been tested in phase I/II clinical trials. MSCs have the potential to become an effective therapeutic strategy for the treatment of ischemic and non-ischemic cardiovascular disorders. The molecular mechanism underlying the efficacy of MSCs in promoting engraftment and accelerating the functional recovery of injury sites is still unclear. It is hypothesized that the mechanisms of paracrine effects for the cardiac repair, optimization of the niche for cell survival, and cardiac remodeling by inflammatory control are involved in the interaction between MSCs and the damaged myocardial environment. This review focuses on recent experimental and clinical findings related to cardiovascular disease. We focus on MSCs, highlighting their roles in cardiovascular disease repair, differentiation, and MSC niche, and discuss their therapeutic efficacy and the current status of MSC-based cardiovascular disease therapies.

Citing Articles

Cryopreservation of mesenchymal stem/stromal cells using a DMSO-free solution is comparable to DMSO-containing cryoprotectants: results of an international multicenter PACT/BEST collaborative study.

Mamo T, Cox C, Demorest C, Fontaine M, Hubel A, Kelley L Cytotherapy. 2024; 26(12):1522-1531.

PMID: 39066775 PMC: 11841823. DOI: 10.1016/j.jcyt.2024.07.001.

Mesenchymal Stem Cell-Conditioned Media Modulate HUVEC Response to HO: Impact on Gene Expression and Potential for Atherosclerosis Intervention.

Alqasoumi A, Alsharidah M, Mahmood A, Elsafadi M, Al Rugaie O, Mohany K Biomed Res Int. 2024; 2024:7726493.

PMID: 39050921 PMC: 11268959. DOI: 10.1155/2024/7726493.

The Effect of Cell Culture Passage on the Efficacy of Mesenchymal Stromal Cells as a Cell Therapy Treatment.

Carmona-Luque M, Ballesteros-Ribelles A, Millan-Lopez A, Blanco A, Nogueras S, Herrera C J Clin Med. 2024; 13(9).

PMID: 38731011 PMC: 11084414. DOI: 10.3390/jcm13092480.

Unlocking the Potential of Extracellular Vesicles as the Next Generation Therapy: Challenges and Opportunities.

Che Shaffi S, Hairuddin O, Mansor S, Syafiq T, Yahaya B Tissue Eng Regen Med. 2024; 21(4):513-527.

PMID: 38598059 PMC: 11087396. DOI: 10.1007/s13770-024-00634-4.

Differentiation of placenta-derived MSCs cultured in human platelet lysate: a xenofree supplement.

Poomani M, Regurajan R, Perumal R, Ramachandran A, Mariappan I, Muthan K 3 Biotech. 2024; 14(4):116.

PMID: 38524240 PMC: 10959853. DOI: 10.1007/s13205-024-03966-z.

References

. Management of peripheral arterial disease (PAD). TransAtlantic Inter-Society Consensus (TASC). Section D: chronic critical limb ischaemia. Eur J Vasc Endovasc Surg. 2000; 19 Suppl A:S144-243. View

Jacobs B, Browner W . Ginkgo biloba: a living fossil. Am J Med. 2000; 108(4):341-2. DOI: 10.1016/s0002-9343(00)00290-4. View

Kehat I, Snir M, Segev H, Amit M, Gepstein A, Livne E . Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. J Clin Invest. 2001; 108(3):407-14. PMC: 209357. DOI: 10.1172/JCI12131. View

Kamihata H, Matsubara H, Nishiue T, Fujiyama S, Tsutsumi Y, Ozono R . Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines. Circulation. 2001; 104(9):1046-52. DOI: 10.1161/hc3501.093817. View

Toma C, Pittenger M, Cahill K, Byrne B, Kessler P . Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation. 2002; 105(1):93-8. DOI: 10.1161/hc0102.101442. View

Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni P, Matteucci P . Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002; 99(10):3838-43. DOI: 10.1182/blood.v99.10.3838. View

Shake J, Gruber P, Baumgartner W, Senechal G, Meyers J, Mark Redmond J . Mesenchymal stem cell implantation in a swine myocardial infarct model: engraftment and functional effects. Ann Thorac Surg. 2002; 73(6):1919-25; discussion 1926. DOI: 10.1016/s0003-4975(02)03517-8. View

Boheler K, Czyz J, Tweedie D, Yang H, Anisimov S, Wobus A . Differentiation of pluripotent embryonic stem cells into cardiomyocytes. Circ Res. 2002; 91(3):189-201. DOI: 10.1161/01.res.0000027865.61704.32. View

Chase M . Multiple disseminated granulomata in sensitized guinea pigs. Ryumachi. 1975; 15(4):389-90. View

10.

Fukuhara S, Tomita S, Yamashiro S, Morisaki T, Yutani C, Kitamura S . Direct cell-cell interaction of cardiomyocytes is key for bone marrow stromal cells to go into cardiac lineage in vitro. J Thorac Cardiovasc Surg. 2003; 125(6):1470-80. DOI: 10.1016/s0022-5223(02)73610-6. View

11.

Fijnvandraat A, van Ginneken A, Schumacher C, Boheler K, Lekanne Deprez R, Christoffels V . Cardiomyocytes purified from differentiated embryonic stem cells exhibit characteristics of early chamber myocardium. J Mol Cell Cardiol. 2003; 35(12):1461-72. DOI: 10.1016/j.yjmcc.2003.09.011. View

12.

Bartel D . MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2):281-97. DOI: 10.1016/s0092-8674(04)00045-5. View

13.

Rolletschek A, Blyszczuk P, Wobus A . Embryonic stem cell-derived cardiac, neuronal and pancreatic cells as model systems to study toxicological effects. Toxicol Lett. 2004; 149(1-3):361-9. DOI: 10.1016/j.toxlet.2003.12.064. View

14.

Pittenger M, Martin B . Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res. 2004; 95(1):9-20. DOI: 10.1161/01.RES.0000135902.99383.6f. View

15.

Coats P, Wadsworth R . Marriage of resistance and conduit arteries breeds critical limb ischemia. Am J Physiol Heart Circ Physiol. 2005; 288(3):H1044-50. DOI: 10.1152/ajpheart.00773.2004. View

16.

Tang G, Chang D, Sarkar R, Wang R, Messina L . The effect of gradual or acute arterial occlusion on skeletal muscle blood flow, arteriogenesis, and inflammation in rat hindlimb ischemia. J Vasc Surg. 2005; 41(2):312-20. DOI: 10.1016/j.jvs.2004.11.012. View

17.

Mann D, Bristow M . Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation. 2005; 111(21):2837-49. DOI: 10.1161/CIRCULATIONAHA.104.500546. View

18.

Amado L, Saliaris A, Schuleri K, John M, Xie J, Cattaneo S . Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proc Natl Acad Sci U S A. 2005; 102(32):11474-9. PMC: 1183573. DOI: 10.1073/pnas.0504388102. View

19.

Piao H, Youn T, Kwon J, Kim Y, Bae J, Bora-Sohn . Effects of bone marrow derived mesenchymal stem cells transplantation in acutely infarcting myocardium. Eur J Heart Fail. 2005; 7(5):730-8. DOI: 10.1016/j.ejheart.2004.09.019. View

20.

Dzau V, Gnecchi M, Pachori A . Enhancing stem cell therapy through genetic modification. J Am Coll Cardiol. 2005; 46(7):1351-3. DOI: 10.1016/j.jacc.2005.07.023. View